keyword
MENU ▼
Read by QxMD icon Read
search

metastatic melanoma

keyword
https://www.readbyqxmd.com/read/27906109/primary-melanoma-of-the-small-bowel-revealed-by-gastrointestinal-bleeding-a-case-report
#1
B Ait Idir, A Riany, A Jahid, B Chad
BACKGROUND: Primary melanoma of the small bowel is extremely rare. Only a limited number of cases have been described in the literature. Mostly, the small intestine is affected by metastatic tumors of other primary lesions, especially cutaneous. CASE PRESENTATION: We report the case of a 75-year-old North African woman with a small bowel melanoma. The diagnosis was made by histological examination and immunohistochemical profile matching after a segmental small bowel resection...
December 1, 2016: Journal of Medical Case Reports
https://www.readbyqxmd.com/read/27906105/pancreatic-metastases-from-ocular-malignant-melanoma-the-use-of-endoscopic-ultrasound-guided-fine-needle-aspiration-to-establish-a-definitive-cytologic-diagnosis-a-case-report
#2
Diogo Turiani Hourneaux De Moura, Danielle Azevedo Chacon, Ryan Tanigawa, Martin Coronel, Spencer Cheng, Éverson L A Artifon, José Jukemura, Eduardo Guimarães Hourneaux De Moura
BACKGROUND: When encountering solid pancreatic lesions, nonpancreatic primary metastases are rare and differentiating a metastasis from a primary neoplastic lesion is challenging. The clinical presentation and radiologic features can be similar and the possibility of a pancreatic metastasis should be considered when the patient refers to a history of a different primary cancer. Endoscopic ultrasound offers a key anatomical advantage in accessing the pancreas and endoscopic ultrasound-guided fine-needle aspiration has become the gold standard method for diagnosing pancreatic lesions...
December 1, 2016: Journal of Medical Case Reports
https://www.readbyqxmd.com/read/27905824/improved-survival-and-complete-response-rates-in-patients-with-advanced-melanoma-treated-with-concurrent-ipilimumab-and-radiotherapy-versus-ipilimumab-alone
#3
Kristian M Koller, Heath B Mackley, Jason Liu, Henry Wagner, Giampaolo Talamo, Todd D Schell, Colette Pameijer, Rogerio I Neves, Bryan Anderson, Kathleen M Kokolus, Carol A Mallon, Joseph J Drabick
There is a growing body of evidence supporting the synergistic roles of radiotherapy and immunotherapy in the treatment of malignancy. Published case studies of the abscopal effect have been reported with the use of ipilimumab and radiotherapy in metastatic melanoma, but evidence supporting the routine use of this combination of therapy is limited. We conducted a retrospective analysis to evaluate patients treated with ipilimumab for advanced melanoma at a single institution from May 2011 to June 2015. Patients were grouped into those who had received concurrent radiotherapy while on ipilimumab (Ipi-RT), and those who did not...
December 1, 2016: Cancer Biology & Therapy
https://www.readbyqxmd.com/read/27905182/optimizing-combination-dabrafenib-and-trametinib-therapy-in-braf-mutation-positive-advanced-melanoma-patients-guidelines-from-australian-melanoma-medical-oncologists
#4
Victoria Atkinson, Georgina V Long, Alexander M Menzies, Grant McArthur, Matteo S Carlino, Michael Millward, Rachel Roberts-Thomson, Benjamin Brady, Richard Kefford, Andrew Haydon, Jonathan Cebon
BRAF mutations occur commonly in metastatic melanomas and inhibition of mutant BRAF and the downstream kinase MEK results in rapid tumor regression and prolonged survival in patients. Combined therapy with BRAF and MEK inhibition improves response rate, progression free survival and overall survival compared with single agent BRAF inhibition, and reduces the skin toxicity that is seen with BRAF inhibitor monotherapy. However, this combination is associated with an increase in other toxicities, particularly drug-related pyrexia, which affects approximately 50% of patients treated with dabrafenib and trametinib (CombiDT)...
December 2016: Asia-Pacific Journal of Clinical Oncology
https://www.readbyqxmd.com/read/27903862/improved-cancer-immunotherapy-by-a-cd25-mimobody-conferring-selectivity-to-human-interleukin-2
#5
Natalia Arenas-Ramirez, Chao Zou, Simone Popp, Daniel Zingg, Barbara Brannetti, Emmanuelle Wirth, Thomas Calzascia, Jiri Kovarik, Lukas Sommer, Gerhard Zenke, Janine Woytschak, Catherine H Regnier, Andreas Katopodis, Onur Boyman
Interleukin-2 (IL-2) immunotherapy is an attractive approach in treating advanced cancer. However, by binding to its IL-2 receptor α (CD25) subunit, IL-2 exerts unwanted effects, including stimulation of immunosuppressive regulatory T cells (Tregs) and contribution to vascular leak syndrome. We used a rational approach to develop a monoclonal antibody to human IL-2, termed NARA1, which acts as a high-affinity CD25 mimic, thereby minimizing association of IL-2 with CD25. The structure of the IL-2-NARA1 complex revealed that NARA1 occupies the CD25 epitope of IL-2 and precisely overlaps with CD25...
November 30, 2016: Science Translational Medicine
https://www.readbyqxmd.com/read/27903181/prognostic-factors-for-melanoma-brain-metastases-treated-with-stereotactic-radiosurgery
#6
Shelly X Bian, David Routman, Jonathan Liu, Dongyun Yang, Susan Groshen, Gabriel Zada, Nicholas Trakul, Michael K Wong, Cheng Yu, Eric L Chang
OBJECTIVE Stereotactic radiosurgery (SRS) is routinely used to treat brain metastases from melanoma due to their radioresistant nature. The median survival for these patients is 4-6 months, according to earlier studies. The aim of this study was to evaluate prognostic factors that influence survival in patients with metastatic melanoma to the brain treated with SRS. METHODS This retrospective analysis included all patients with melanoma brain metastases treated with SRS at the University of Southern California between 1994 and 2015...
December 2016: Journal of Neurosurgery
https://www.readbyqxmd.com/read/27900851/metastatic-pathways-in-patients-with-cutaneous-melanoma
#7
REVIEW
Nikki R Adler, Andrew Haydon, Catriona A McLean, John W Kelly, Victoria J Mar
Metastasis represents the end product of an elaborate biological process, which is determined by a complex interplay between metastatic tumour cells, host factors and homoeostatic mechanisms. Cutaneous melanoma can metastasize haematogenously or lymphogenously. The three predominant models that endeavour to explain the patterns of melanoma progression are the stepwise spread model, the simultaneous spread model and the model of differential spread. The time course to the development of metastases differs between the different metastatic routes...
October 19, 2016: Pigment Cell & Melanoma Research
https://www.readbyqxmd.com/read/27899968/prognostic-significance-of-the-expression-of-nuclear-eukaryotic-translation-initiation-factor-5a2-in-human-melanoma
#8
Shahram Khosravi, Magdalena Martinka, Youwen Zhou, Christopher J Ong
Eukaryotic translation initiation factor 5A2 (EIF5A2) expression is upregulated in various cancers. The present authors previously demonstrated that cytoplasmic EIF5A2 expression increases with melanoma progression and inversely correlates with patient survival. Other studies have suggested that nuclear EIF5A2 may also play a role in oncogenesis. The present study used immunohistochemistry and tissue microarray with a large number of melanocytic lesions (n=459) and demonstrated that nuclear EIF5A2 expression was significantly upregulated between common acquired nevi, dysplastic nevi and primary melanomas, and between primary melanomas and metastatic melanomas...
November 2016: Oncology Letters
https://www.readbyqxmd.com/read/27899956/innovations-that-reach-the-patient-early-health-technology-assessment-and-improving-the-chances-of-coverage-and-implementation
#9
W H van Harten, V P Retèl
With growing concerns for the sustainability of the financial burden that health care-and especially cancer services-poses on the national budgets, the role of health economic analyses in coverage decisions is likely to grow. One of the strategies for the biomedical research field-also in oncology research-to foster coverage and health system implementation, is to anticipate this new role and to involve health technology assessment techniques earlier in various stages of translational research. In this article, we elaborate on the early involvement of health technology assessment in translational research and the concept of Coverage with Evidence Development in The Netherlands Cancer Institute and give two case examples that are currently ongoing: (1) tumour infiltrating lymphocytes therapy for metastatic melanoma; and (2) high-dose chemotherapy for BRCA1-like subgroup in triple-negative breast cancer...
2016: Ecancermedicalscience
https://www.readbyqxmd.com/read/27898753/-oncogen-dependent-regulation-of-the-migration-and-proliferation-of-human-tumor-cells
#10
Tamás M Garay
The high mortality of solid tumors can be attributed to their invasive and metastatic potential that is based on their migration and proliferation. Importantly, growth factor receptor (GF) signaling pathways regulating proliferation and migration are often affected by oncogenic mutations and are important targets for antitumor therapy. We found positive correlation between migration and proliferation in melanoma and lung cancer cells using videomicroscopy, not supporting the "go or grow" hypothesis. Furthermore, the invasion into collagen I matrices from brain tumor spheroids was not impaired upon the inhibition of proliferation...
November 29, 2016: Magyar Onkologia
https://www.readbyqxmd.com/read/27898612/rationale-for-harnessing-the-abscopal-effect-as-potential-treatment-for-metastatic-uveal-melanoma
#11
Sean A Batson, Mark P Breazzano, Ronald W Milam, Eric Shinohara, Douglas B Johnson, Anthony B Daniels
No abstract text is available yet for this article.
2017: International Ophthalmology Clinics
https://www.readbyqxmd.com/read/27895731/advantages-and-disadvantages-of-f-18-fluorodeoxyglucose-positron-emission-tomography-computed-tomography-in-carcinoma-of-unknown-primary
#12
Xiaozhou Yu, Xiaofeng Li, Xiuyu Song, Dong Dai, Lei Zhu, Yanjia Zhu, Jian Wang, Huiqin Zhao, Wengui Xu
Carcinoma of unknown primary is a type of malignant disease where the primary carcinoma cannot be identified by conventional examination, which presents challenges in diagnosis and therapy. This study aims to evaluate the detailed clinical value and indications of using fluorine-18-2-fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography (F-18 FDG PET/CT) in a large sample. A total of 449 patients who were selected under strict standards were retrospectively included in this study. F-18 FDG PET/CT accurately detected the primary carcinoma in 115 of 449 patients whose primaries could not be detected by conventional examination (25...
November 2016: Oncology Letters
https://www.readbyqxmd.com/read/27893188/dek-oncogene-is-overexpressed-during-melanoma-progression
#13
Erica Riveiro-Falkenbach, Yolanda Ruano, Rosa M García-Martín, David Lora, Metehan Cifdaloz, Francesco Acquadro, Claudio Ballestin, Pablo L Ortiz-Romero, María S Soengas, José L Rodríguez-Peralto
DEK is an oncoprotein involved in a variety of cellular functions, such as DNA repair, replication and transcriptional control. DEK is preferentially expressed in actively proliferating and malignant cells, including melanoma cell lines in which DEK was previously demonstrated to play a critical role in proliferation and chemoresistance. Still, the impact of this protein in melanoma progression remains unclear. Thus, we performed a comprehensive analysis of DEK expression in different melanocytic tumors. The immunostaining results of 303 tumors demonstrated negligible DEK expression in benign lesions...
November 28, 2016: Pigment Cell & Melanoma Research
https://www.readbyqxmd.com/read/27892777/uveitis-and-papillitis-in-the-setting-of-dabrafenib-and-trametinib-therapy-for-metastatic-melanoma-a-case-report
#14
Jennifer Lim, Anna J Lomax, Catriona McNeil, Brian Harrisberg
PURPOSE: To report the diagnosis of acute VKH-like syndrome as a complication from dabrafenib (a serine/threonine inhibitor of BRAF V600) and trametinib (a MEK inhibitor). In combination, these targeted agents have been shown to prolong overall survival and progression free survival in BRAF mutant metastatic melanoma. METHODS: Retrospective medical chart review including radiologic and ophthalmologic investigations. RESULTS: A patient with metastatic melanoma being treated with dabrafenib and trametinib for 2 months presented with 1 week of visual blurring...
November 28, 2016: Ocular Immunology and Inflammation
https://www.readbyqxmd.com/read/27892653/low-baseline-levels-of-nk-cells-may-predict-a-positive-response-to-ipilimumab-in-melanoma-therapy
#15
Julia K Tietze, Daniela Angelova, Markus V Heppt, Thomas Ruzicka, Carola Berking
The introduction of immune checkpoint blockade (ICB) has been a breakthrough in the therapy of metastatic melanoma. The influence of ICB on T cell populations has been studied extensively but little is known about the effect on NK cells. In this study, we analysed the relative and absolute amounts of NK cells and of the subpopulations of CD56(dim) and CD56(bright) NK cells among the peripheral blood mononuclear cells (PBMCs) of 32 patients with metastatic melanoma before and under treatment with ipilimumab or pembrolizumab by flow cytometry...
November 28, 2016: Experimental Dermatology
https://www.readbyqxmd.com/read/27889195/metastasectomy-in-cutaneous-melanoma
#16
REVIEW
K Lasithiotakis, O Zoras
Metastectomy remains the only treatment in malignant melanoma to offer complete pathologic response within a few days of in-hospital stay. It has been historically associated with the highest survival rates in the literature reported for patients of this stage. However, only a minority of patients are amenable to curative resection of distant metastatic disease. This patient group exhibit slow growing oligometastases as indicated by: a. Long disease free interval after treatment of their primary tumours and b...
November 13, 2016: European Journal of Surgical Oncology
https://www.readbyqxmd.com/read/27883956/efficacy-of-braf-inhibitors-in-asian-metastatic-melanoma-patients-potential-implications-of-genomic-sequencing-in-braf-mutated-melanoma
#17
Hee Kyung Kim, Sunyoung Lee, Kyung Kim, Mi Hwa Heo, Hansang Lee, Jinhyun Cho, Nayoung K D Kim, Woongyang Park, Su Jin Lee, Jung Han Kim, Kee-Taek Jang, Sang-Hee Choi, Jeeyun Lee
BACKGROUND: The BRAF inhibitors vemurafenib and dabrafenib are currently the standard treatment for metastatic melanoma with BRAF V600 mutations. However, given the rarity of noncutaneous melanoma, including acral and mucosal subtypes, the efficacy of BRAF inhibitors for this subset of patients has not been extensively investigated. Acquired resistance generally appears 6 to 8 months after treatment with a BRAF inhibitor, and the mechanism of resistance is not well established. METHODS: We examined treatment outcomes for patients diagnosed with metastatic melanoma and treated with BRAF inhibitors at Samsung Medical Center between April 2013 and December 2015...
November 21, 2016: Translational Oncology
https://www.readbyqxmd.com/read/27882779/ipilimumab-from-preclinical-development-to-future-clinical-perspectives-in-melanoma
#18
Paul Letendre, Varun Monga, Mohammed Milhem, Yousef Zakharia
The arsenal for the treatment of metastatic melanoma is limited. A new approach to therapy using checkpoint blockade has improved overall survival in this patient population. Ipilimumab a CTLA-4 monoclonal antibody is a first in class drug that has pioneered this revolution. In this review, the authors provide an account of the different stages that led to the development of ipilimumab, its approval in the clinical setting for the treatment of advanced melanoma and ongoing investigations of combinatorial immune therapy...
November 24, 2016: Future Oncology
https://www.readbyqxmd.com/read/27881589/metastatic-melanoma-after-23%C3%A2-years-of-primary-ocular-melanoma
#19
Supriya Ramesh Karde, Prashant Ramesh Bhand, Nagabathula Ramesh, Sacchin Arockiam
We describe a case of 52-year-old man who presented with an episode of tonic-clonic seizures. He had right ocular melanoma 23 years ago with subsequent enucleation which was the standard treatment at that time. CT scans of the brain and of the thorax-abdomen-pelvis revealed widespread metastatic lesions in the brain, lung and liver. Further investigations including bronchoscopy with cytopathology uncovered that the metastatic disease was a recurrence of ocular melanoma. He received palliative radiotherapy and died 6 months later...
November 23, 2016: BMJ Case Reports
https://www.readbyqxmd.com/read/27881588/glucocorticoids-did-not-reverse-type-1-diabetes-mellitus-secondary-to-pembrolizumab-in-a-patient-with-metastatic-melanoma
#20
Jasna Aleksova, Peter K H Lau, Georgia Soldatos, Grant McArthur
Immune checkpoint inhibitors offer patients with advanced melanoma substantial improvements in survival. Unlike chemotherapy, immune checkpoint inhibitors such as ipilimumab and pembrolizumab cause unique immune-related adverse events (irAEs), including the development of endocrinopathies. We report a case of a man aged 60 years who developed diabetic ketoacidosis (DKA) following the use of pembrolizumab for the treatment of metastatic melanoma. He received four cycles of ipilimumab, before proceeding to pembrolizumab...
November 23, 2016: BMJ Case Reports
keyword
keyword
15684
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"